Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (791-800 of 962) with videos related to

Pageof 97
Sort By:
European Heart Journal|October 23, 2015
Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54Marc P Bonaca, Deepak L Bhatt, P Gabriel Steg, et al.
Atherosclerosis|February 2, 2020
Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS studyPly Chichareon, Rodrigo Modolo, Norihiro Kogame, et al.
JAMA|March 18, 2015
Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trialDean J Kereiakes, Robert W Yeh, Joseph M Massaro, et al.
Journal of the American College of Cardiology|February 28, 2024
Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMIDouglas L Mann, Johny Nicolas, Brian Claggett, et al.
JAMA Cardiology|November 7, 2019
Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical TrialPly Chichareon, Rodrigo Modolo, Laura Kerkmeijer, et al.
The Canadian Journal of Cardiology|May 26, 2020
Influence of Bleeding Risk on Outcomes of Radial and Femoral Access for Percutaneous Coronary Intervention: An Analysis From the GLOBAL LEADERS TrialChao Gao, Piotr Buszman, Paweł Buszman, et al.
European Heart Journal|September 14, 2015
Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trialGérard Helft, Philippe Gabriel Steg, Claude Le Feuvre, et al.
European Heart Journal|May 24, 2019
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trialHarvey D White, Ph Gabriel Steg, Michael Szarek, et al.
JACC. Cardiovascular Interventions|March 24, 2017
Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS RegistryMichela Faggioni, Usman Baber, Samantha Sartori, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|September 10, 2019
Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trialKuniaki Takahashi, Ply Chichareon, Rodrigo Modolo, et al.
Pageof 97

Showing results (791-800 of 962) with videos related to

Sort By:
Pageof 97
European Heart Journal|October 23, 2015
Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54Marc P Bonaca, Deepak L Bhatt, P Gabriel Steg, et al.
Atherosclerosis|February 2, 2020
Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS studyPly Chichareon, Rodrigo Modolo, Norihiro Kogame, et al.
JAMA|March 18, 2015
Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trialDean J Kereiakes, Robert W Yeh, Joseph M Massaro, et al.
Journal of the American College of Cardiology|February 28, 2024
Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMIDouglas L Mann, Johny Nicolas, Brian Claggett, et al.
JAMA Cardiology|November 7, 2019
Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical TrialPly Chichareon, Rodrigo Modolo, Laura Kerkmeijer, et al.
The Canadian Journal of Cardiology|May 26, 2020
Influence of Bleeding Risk on Outcomes of Radial and Femoral Access for Percutaneous Coronary Intervention: An Analysis From the GLOBAL LEADERS TrialChao Gao, Piotr Buszman, Paweł Buszman, et al.
European Heart Journal|September 14, 2015
Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trialGérard Helft, Philippe Gabriel Steg, Claude Le Feuvre, et al.
European Heart Journal|May 24, 2019
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trialHarvey D White, Ph Gabriel Steg, Michael Szarek, et al.
JACC. Cardiovascular Interventions|March 24, 2017
Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS RegistryMichela Faggioni, Usman Baber, Samantha Sartori, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|September 10, 2019
Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trialKuniaki Takahashi, Ply Chichareon, Rodrigo Modolo, et al.
Pageof 97